Business Development & International Partnership

The Food and Drugs Authority (FDA) Ghana is actively fostering business development and international partnerships to enhance public health and safety, and strengthen regulatory systems across Africa. Operating under the Public Health Act, 2012 (Act 851), the FDA regulates a wide array of products, including food, drugs, cosmetics, and medical devices. This article examines the legal framework underpinning the FDA's collaborative efforts, highlighting the stringent regulatory requirements for product registration, import/export, and facility licensing that international partners and businesses must navigate. It also touches upon Ghana's intellectual property and competition law landscape, which are crucial considerations for foreign direct investment and strategic alliances within the sectors regulated by the FDA.

The Food and Drugs Authority (FDA) Ghana has strategically positioned itself as a key player in fostering business development and international collaborations, extending its influence beyond national borders to strengthen regulatory systems across the African continent. This proactive approach is spearheaded by its Business Development and International Partnerships (BDIP) Directorate and the Strategy Partnerships and International Collaborations Department (SPICD), which are mandated to drive strategic alliances and enhance regulatory excellence.

For legal practitioners advising clients on market entry, product development, or strategic partnerships in Ghana's regulated sectors, understanding the FDA's expansive mandate and its commitment to international standards is paramount. This article delves into the legal and regulatory landscape governing business development and international partnerships within the FDA's purview, offering insights into the compliance requirements and the broader legal environment that shapes these collaborations. It aims to equip legal professionals with a comprehensive understanding of the opportunities and challenges presented by Ghana's regulatory framework.

The regulatory authority of the FDA Ghana is primarily derived from the Public Health Act, 2012 (Act 851), which consolidated and updated previous legislation, including the Food and Drugs Law of 1992 (PNDCL 305B). This foundational Act empowers the FDA to regulate the manufacture, importation, exportation, distribution, sale, and advertisement of a diverse range of products, including human and veterinary drugs, food, biological products, cosmetics, medical devices, and household chemical substances. The FDA's functions, as detailed in Parts 6, 7, and 8 of Act 851, encompass enforcing standards, registering products, licensing facilities, issuing import and export permits, conducting market surveillance, and approving clinical trials.

In line with its mandate, the FDA has actively pursued international collaborations, providing training and technical assistance to National Regulatory Agencies (NRAs) in numerous African countries. These partnerships aim to harmonize regulatory standards and practices, reflecting Ghana's commitment to global regulatory excellence, as evidenced by its designation as a World Health Organization (WHO) Maturity Level 3 institution and a Regional Centre of Regulatory Excellence (RCORE). Such engagements often involve Memoranda of Understanding (MOUs) with partner organizations, facilitating knowledge exchange and resource sharing to address common public health challenges.

Navigating business development and international partnerships in Ghana's FDA-regulated sectors requires meticulous adherence to the Public Health Act, 2012 (Act 851) and its subsidiary regulations. A critical aspect for any business, local or international, is product registration. Section 97 of Act 851 mandates that no person shall manufacture, import, export, distribute, sell, or supply food unless it has been registered with the FDA. Similar provisions apply to drugs, cosmetics, and medical devices. The registration process is rigorous, requiring submission of a business registration certificate, certificate of analysis from the country of origin, a certificate of manufacture and free sale, and product samples for laboratory analysis. Importantly, the FDA has a zero-tolerance policy for unregistered imported products in commercial quantities, which may lead to re-exportation or confiscation.

Beyond product registration, businesses must also secure appropriate licenses for manufacturing and storage facilities, as well as import and export permits for FDA-regulated products. The FDA has streamlined some processes, notably through an MOU with the Ghana Standards Authority (GSA) in June 2022, allowing businesses to apply for FDA registration and GSA certification through a single system, thereby reducing duplication and enhancing efficiency. This harmonization is a positive development for businesses seeking to comply with both regulatory bodies.

Intellectual property (IP) protection is another vital consideration for international partnerships. Ghana's IP framework includes the Patents Act, 2003 (Act 657), the Trademarks Act, 2004 (Act 664), and the Copyright Act, 2005 (Act 690). While Ghana's IP laws are largely compliant with international treaties like TRIPS, enforcement can be slow, and issues like counterfeiting persist, particularly in sectors such as pharmaceuticals and cosmetics. Therefore, robust IP strategies, including local registration and proactive enforcement, are crucial for foreign investors. Furthermore, while Ghana has the Protection Against Unfair Competition Act, 2000 (Act 589), a comprehensive competition law is still in development, with ongoing efforts to align with ECOWAS regional competition frameworks.

Recent legislative developments concerning foreign investment are also pertinent. The Ghana Investment Promotion Centre Act, 2013 (Act 865) previously set minimum capital requirements for foreign participation. However, the recently passed Ghana Investment Promotion Act (GIPA) 2026, which awaits presidential assent, introduces significant changes, including the removal of blanket minimum foreign capital thresholds for joint ventures and wholly foreign-owned enterprises. Nevertheless, specific capital and skilled Ghanaian workforce requirements will continue to apply to trading enterprises, with a minimum investment of USD 500,000 in cash equity and at least 75% skilled Ghanaian workforce. These changes aim to create a more attractive investment environment while ensuring local participation and benefit.

The FDA Ghana's proactive stance on business development and international partnerships signals a dynamic regulatory environment that prioritizes public health while seeking to facilitate legitimate trade and investment. For legal practitioners, advising clients on market entry or expansion in Ghana's regulated sectors necessitates a deep understanding of the Public Health Act, 2012 (Act 851), its stringent product registration and licensing requirements, and the FDA's various guidelines. The ongoing harmonization efforts with bodies like the Ghana Standards Authority are positive steps, but the onus remains on businesses to ensure full compliance.

Practitioners should also closely monitor the implementation of the new Ghana Investment Promotion Act (GIPA) 2026, as its provisions will significantly impact foreign investment structures and requirements. Furthermore, while Ghana possesses a foundational intellectual property framework, strategic advice on IP protection and enforcement is critical given existing challenges. As Ghana continues to strengthen its regulatory landscape and foster international collaborations, legal professionals must stay abreast of these developments to effectively guide their clients through the complexities and opportunities within this evolving market.